Status and phase
Conditions
Treatments
About
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
457 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Mary A Kelley, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal